

Global Vaccine Particulate Adjuvants Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/G2FBDDC8F438EN.html>

Date: October 2025

Pages: 141

Price: US\$ 3,200.00 (Single User License)

ID: G2FBDDC8F438EN

Abstracts

Report Overview

The global Vaccine Particulate Adjuvants market size was estimated at USD 320.45 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.75% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Vaccine Particulate Adjuvants market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Vaccine Particulate Adjuvants market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Vaccine Particulate Adjuvants market

Global Vaccine Particulate Adjuvants Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Brenntag Biosector (Denmark)
CSL Limited (Australia)
SEPPIC (France)
AgenusInc (US)
NovavaxInc (US)
SPI PharmaInc (US)
Invivogen (US)
Avanti Polar LipidsInc (US)
MVP LaboratoriesInc (US)
OZ Biosciences (France)

Market Segmentation (by Type)

Oral
Subcutaneous
Intranasal
Intramuscular
Intradermal
Others

Market Segmentation (by Application)

Infectious Diseases
Cancer
Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Vaccine Particulate Adjuvants Market

Overview of the regional outlook of the Vaccine Particulate Adjuvants Market.

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Vaccine Particulate Adjuvants Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Vaccine Particulate Adjuvants, their

output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Vaccine Particulate Adjuvants

1.2 Key Market Segments

1.2.1 Vaccine Particulate Adjuvants Segment by Type

1.2.2 Vaccine Particulate Adjuvants Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 VACCINE PARTICULATE ADJUVANTS MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Vaccine Particulate Adjuvants Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Vaccine Particulate Adjuvants Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 VACCINE PARTICULATE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Vaccine Particulate Adjuvants Product Life Cycle

3.3 Global Vaccine Particulate Adjuvants Sales by Manufacturers (2020-2025)

3.4 Global Vaccine Particulate Adjuvants Revenue Market Share by Manufacturers (2020-2025)

3.5 Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Vaccine Particulate Adjuvants Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Vaccine Particulate Adjuvants Market Competitive Situation and Trends

3.8.1 Vaccine Particulate Adjuvants Market Concentration Rate

3.8.2 Global 5 and 10 Largest Vaccine Particulate Adjuvants Players Market Share by

Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 VACCINE PARTICULATE ADJUVANTS INDUSTRY CHAIN ANALYSIS

4.1 Vaccine Particulate Adjuvants Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF VACCINE PARTICULATE ADJUVANTS MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global Vaccine Particulate Adjuvants Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to Vaccine Particulate Adjuvants

Market

5.7 ESG Ratings of Leading Companies

6 VACCINE PARTICULATE ADJUVANTS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2020-2025)

6.3 Global Vaccine Particulate Adjuvants Market Size Market Share by Type (2020-2025)

6.4 Global Vaccine Particulate Adjuvants Price by Type (2020-2025)

7 VACCINE PARTICULATE ADJUVANTS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Vaccine Particulate Adjuvants Market Sales by Application (2020-2025)

7.3 Global Vaccine Particulate Adjuvants Market Size (M USD) by Application (2020-2025)

7.4 Global Vaccine Particulate Adjuvants Sales Growth Rate by Application (2020-2025)

8 VACCINE PARTICULATE ADJUVANTS MARKET SALES BY REGION

8.1 Global Vaccine Particulate Adjuvants Sales by Region

8.1.1 Global Vaccine Particulate Adjuvants Sales by Region

8.1.2 Global Vaccine Particulate Adjuvants Sales Market Share by Region

8.2 Global Vaccine Particulate Adjuvants Market Size by Region

8.2.1 Global Vaccine Particulate Adjuvants Market Size by Region

8.2.2 Global Vaccine Particulate Adjuvants Market Size Market Share by Region

8.3 North America

8.3.1 North America Vaccine Particulate Adjuvants Sales by Country

8.3.2 North America Vaccine Particulate Adjuvants Market Size by Country

8.3.3 U.S. Market Overview

8.3.4 Canada Market Overview

8.3.5 Mexico Market Overview

8.4 Europe

8.4.1 Europe Vaccine Particulate Adjuvants Sales by Country

8.4.2 Europe Vaccine Particulate Adjuvants Market Size by Country

8.4.3 Germany Market Overview

8.4.4 France Market Overview

8.4.5 U.K. Market Overview

8.4.6 Italy Market Overview

8.4.7 Spain Market Overview

8.5 Asia Pacific

8.5.1 Asia Pacific Vaccine Particulate Adjuvants Sales by Region

8.5.2 Asia Pacific Vaccine Particulate Adjuvants Market Size by Region

8.5.3 China Market Overview

8.5.4 Japan Market Overview

8.5.5 South Korea Market Overview

8.5.6 India Market Overview

8.5.7 Southeast Asia Market Overview

8.6 South America

8.6.1 South America Vaccine Particulate Adjuvants Sales by Country

8.6.2 South America Vaccine Particulate Adjuvants Market Size by Country

8.6.3 Brazil Market Overview

8.6.4 Argentina Market Overview

8.6.5 Columbia Market Overview

8.7 Middle East and Africa

8.7.1 Middle East and Africa Vaccine Particulate Adjuvants Sales by Region

8.7.2 Middle East and Africa Vaccine Particulate Adjuvants Market Size by Region

8.7.3 Saudi Arabia Market Overview

8.7.4 UAE Market Overview

8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 VACCINE PARTICULATE ADJUVANTS MARKET PRODUCTION BY REGION

9.1 Global Production of Vaccine Particulate Adjuvants by Region(2020-2025)

9.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Region
(2020-2025)

9.3 Global Vaccine Particulate Adjuvants Production, Revenue, Price and Gross Margin
(2020-2025)

9.4 North America Vaccine Particulate Adjuvants Production

9.4.1 North America Vaccine Particulate Adjuvants Production Growth Rate
(2020-2025)

9.4.2 North America Vaccine Particulate Adjuvants Production, Revenue, Price and
Gross Margin (2020-2025)

9.5 Europe Vaccine Particulate Adjuvants Production

9.5.1 Europe Vaccine Particulate Adjuvants Production Growth Rate (2020-2025)

9.5.2 Europe Vaccine Particulate Adjuvants Production, Revenue, Price and Gross
Margin (2020-2025)

9.6 Japan Vaccine Particulate Adjuvants Production (2020-2025)

9.6.1 Japan Vaccine Particulate Adjuvants Production Growth Rate (2020-2025)

9.6.2 Japan Vaccine Particulate Adjuvants Production, Revenue, Price and Gross
Margin (2020-2025)

9.7 China Vaccine Particulate Adjuvants Production (2020-2025)

9.7.1 China Vaccine Particulate Adjuvants Production Growth Rate (2020-2025)

9.7.2 China Vaccine Particulate Adjuvants Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Brenntag Biosector (Denmark)

10.1.1 Brenntag Biosector (Denmark) Basic Information

10.1.2 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Overview

10.1.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Market Performance

10.1.4 Brenntag Biosector (Denmark) Business Overview

10.1.5 Brenntag Biosector (Denmark) SWOT Analysis

10.1.6 Brenntag Biosector (Denmark) Recent Developments

10.2 CSL Limited (Australia)

10.2.1 CSL Limited (Australia) Basic Information

10.2.2 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Overview

10.2.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Market Performance

10.2.4 CSL Limited (Australia) Business Overview

10.2.5 CSL Limited (Australia) SWOT Analysis

10.2.6 CSL Limited (Australia) Recent Developments

10.3 SEPPIC (France)

10.3.1 SEPPIC (France) Basic Information

10.3.2 SEPPIC (France) Vaccine Particulate Adjuvants Product Overview

10.3.3 SEPPIC (France) Vaccine Particulate Adjuvants Product Market Performance

10.3.4 SEPPIC (France) Business Overview

10.3.5 SEPPIC (France) SWOT Analysis

10.3.6 SEPPIC (France) Recent Developments

10.4 AgenusInc (US)

10.4.1 AgenusInc (US) Basic Information

10.4.2 AgenusInc (US) Vaccine Particulate Adjuvants Product Overview

10.4.3 AgenusInc (US) Vaccine Particulate Adjuvants Product Market Performance

10.4.4 AgenusInc (US) Business Overview

10.4.5 AgenusInc (US) Recent Developments

10.5 NovavaxInc (US)

10.5.1 NovavaxInc (US) Basic Information

10.5.2 NovavaxInc (US) Vaccine Particulate Adjuvants Product Overview

10.5.3 NovavaxInc (US) Vaccine Particulate Adjuvants Product Market Performance

10.5.4 NovavaxInc (US) Business Overview

- 10.5.5 NovavaxInc (US) Recent Developments
- 10.6 SPI PharmaInc (US)
 - 10.6.1 SPI PharmaInc (US) Basic Information
 - 10.6.2 SPI PharmaInc (US) Vaccine Particulate Adjuvants Product Overview
 - 10.6.3 SPI PharmaInc (US) Vaccine Particulate Adjuvants Product Market Performance
 - 10.6.4 SPI PharmaInc (US) Business Overview
 - 10.6.5 SPI PharmaInc (US) Recent Developments
- 10.7 Invivogen (US)
 - 10.7.1 Invivogen (US) Basic Information
 - 10.7.2 Invivogen (US) Vaccine Particulate Adjuvants Product Overview
 - 10.7.3 Invivogen (US) Vaccine Particulate Adjuvants Product Market Performance
 - 10.7.4 Invivogen (US) Business Overview
 - 10.7.5 Invivogen (US) Recent Developments
- 10.8 Avanti Polar LipidsInc (US)
 - 10.8.1 Avanti Polar LipidsInc (US) Basic Information
 - 10.8.2 Avanti Polar LipidsInc (US) Vaccine Particulate Adjuvants Product Overview
 - 10.8.3 Avanti Polar LipidsInc (US) Vaccine Particulate Adjuvants Product Market Performance
 - 10.8.4 Avanti Polar LipidsInc (US) Business Overview
 - 10.8.5 Avanti Polar LipidsInc (US) Recent Developments
- 10.9 MVP LaboratoriesInc (US)
 - 10.9.1 MVP LaboratoriesInc (US) Basic Information
 - 10.9.2 MVP LaboratoriesInc (US) Vaccine Particulate Adjuvants Product Overview
 - 10.9.3 MVP LaboratoriesInc (US) Vaccine Particulate Adjuvants Product Market Performance
 - 10.9.4 MVP LaboratoriesInc (US) Business Overview
 - 10.9.5 MVP LaboratoriesInc (US) Recent Developments
- 10.10 OZ Biosciences (France)
 - 10.10.1 OZ Biosciences (France) Basic Information
 - 10.10.2 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Overview
 - 10.10.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Market Performance
 - 10.10.4 OZ Biosciences (France) Business Overview
 - 10.10.5 OZ Biosciences (France) Recent Developments

11 VACCINE PARTICULATE ADJUVANTS MARKET FORECAST BY REGION

11.1 Global Vaccine Particulate Adjuvants Market Size Forecast

11.2 Global Vaccine Particulate Adjuvants Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Vaccine Particulate Adjuvants Market Size Forecast by Country

11.2.3 Asia Pacific Vaccine Particulate Adjuvants Market Size Forecast by Region

11.2.4 South America Vaccine Particulate Adjuvants Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Vaccine Particulate Adjuvants by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

12.1 Global Vaccine Particulate Adjuvants Market Forecast by Type (2026-2033)

12.1.1 Global Forecasted Sales of Vaccine Particulate Adjuvants by Type (2026-2033)

12.1.2 Global Vaccine Particulate Adjuvants Market Size Forecast by Type (2026-2033)

12.1.3 Global Forecasted Price of Vaccine Particulate Adjuvants by Type (2026-2033)

12.2 Global Vaccine Particulate Adjuvants Market Forecast by Application (2026-2033)

12.2.1 Global Vaccine Particulate Adjuvants Sales (K MT) Forecast by Application

12.2.2 Global Vaccine Particulate Adjuvants Market Size (M USD) Forecast by Application (2026-2033)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Vaccine Particulate Adjuvants Market Size Comparison by Region (M USD)

Table 5. Global Vaccine Particulate Adjuvants Sales (K MT) by Manufacturers
(2020-2025)

Table 6. Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers
(2020-2025)

Table 7. Global Vaccine Particulate Adjuvants Revenue (M USD) by Manufacturers
(2020-2025)

Table 8. Global Vaccine Particulate Adjuvants Revenue Share by Manufacturers
(2020-2025)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine
Particulate Adjuvants as of 2024)

Table 10. Global Market Vaccine Particulate Adjuvants Average Price (USD/KG) of Key
Manufacturers (2020-2025)

Table 11. Manufacturers? Manufacturing Sites, Areas Served

Table 12. Manufacturers? Product Type

Table 13. Global Vaccine Particulate Adjuvants Manufacturers Market Concentration
Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Market Overview of Key Raw Materials

Table 16. Midstream Market Analysis

Table 17. Downstream Customer Analysis

Table 18. Key Development Trends

Table 19. Driving Factors

Table 20. Vaccine Particulate Adjuvants Market Challenges

Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026

Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027

Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026

Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading
Countries

Table 25. Global Vaccine Particulate Adjuvants Sales by Type (K MT)

Table 26. Global Vaccine Particulate Adjuvants Market Size by Type (M USD)

Table 27. Global Vaccine Particulate Adjuvants Sales (K MT) by Type (2020-2025)

Table 28. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2020-2025)
Table 29. Global Vaccine Particulate Adjuvants Market Size (M USD) by Type (2020-2025)
Table 30. Global Vaccine Particulate Adjuvants Market Size Share by Type (2020-2025)
Table 31. Global Vaccine Particulate Adjuvants Price (USD/KG) by Type (2020-2025)
Table 32. Global Vaccine Particulate Adjuvants Sales (K MT) by Application
Table 33. Global Vaccine Particulate Adjuvants Market Size by Application
Table 34. Global Vaccine Particulate Adjuvants Sales by Application (2020-2025) & (K MT)
Table 35. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2020-2025)
Table 36. Global Vaccine Particulate Adjuvants Market Size by Application (2020-2025) & (M USD)
Table 37. Global Vaccine Particulate Adjuvants Market Share by Application (2020-2025)
Table 38. Global Vaccine Particulate Adjuvants Sales Growth Rate by Application (2020-2025)
Table 39. Global Vaccine Particulate Adjuvants Sales by Region (2020-2025) & (K MT)
Table 40. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2020-2025)
Table 41. Global Vaccine Particulate Adjuvants Market Size by Region (2020-2025) & (M USD)
Table 42. Global Vaccine Particulate Adjuvants Market Size Market Share by Region (2020-2025)
Table 43. North America Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K MT)
Table 44. North America Vaccine Particulate Adjuvants Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K MT)
Table 46. Europe Vaccine Particulate Adjuvants Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Vaccine Particulate Adjuvants Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Vaccine Particulate Adjuvants Market Size by Region (2020-2025) & (M USD)
Table 49. South America Vaccine Particulate Adjuvants Sales by Country (2020-2025) & (K MT)

Table 50. South America Vaccine Particulate Adjuvants Market Size by Country (2020-2025) & (M USD)

Table 51. Middle East and Africa Vaccine Particulate Adjuvants Sales by Region (2020-2025) & (K MT)

Table 52. Middle East and Africa Vaccine Particulate Adjuvants Market Size by Region (2020-2025) & (M USD)

Table 53. Global Vaccine Particulate Adjuvants Production (K MT) by Region(2020-2025)

Table 54. Global Vaccine Particulate Adjuvants Revenue (US\$ Million) by Region (2020-2025)

Table 55. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2020-2025)

Table 56. Global Vaccine Particulate Adjuvants Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 57. North America Vaccine Particulate Adjuvants Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. Europe Vaccine Particulate Adjuvants Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Japan Vaccine Particulate Adjuvants Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 60. China Vaccine Particulate Adjuvants Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 61. Brenntag Biosector (Denmark) Basic Information

Table 62. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Overview

Table 63. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 64. Brenntag Biosector (Denmark) Business Overview

Table 65. Brenntag Biosector (Denmark) SWOT Analysis

Table 66. Brenntag Biosector (Denmark) Recent Developments

Table 67. CSL Limited (Australia) Basic Information

Table 68. CSL Limited (Australia) Vaccine Particulate Adjuvants Product Overview

Table 69. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 70. CSL Limited (Australia) Business Overview

Table 71. CSL Limited (Australia) SWOT Analysis

Table 72. CSL Limited (Australia) Recent Developments

Table 73. SEPPIC (France) Basic Information

Table 74. SEPPIC (France) Vaccine Particulate Adjuvants Product Overview

Table 75. SEPPIC (France) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 76. SEPPIC (France) Business Overview

Table 77. SEPPIC (France) SWOT Analysis

Table 78. SEPPIC (France) Recent Developments

Table 79. AgenusInc (US) Basic Information

Table 80. AgenusInc (US) Vaccine Particulate Adjuvants Product Overview

Table 81. AgenusInc (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 82. AgenusInc (US) Business Overview

Table 83. AgenusInc (US) Recent Developments

Table 84. NovavaxInc (US) Basic Information

Table 85. NovavaxInc (US) Vaccine Particulate Adjuvants Product Overview

Table 86. NovavaxInc (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 87. NovavaxInc (US) Business Overview

Table 88. NovavaxInc (US) Recent Developments

Table 89. SPI PharmaInc (US) Basic Information

Table 90. SPI PharmaInc (US) Vaccine Particulate Adjuvants Product Overview

Table 91. SPI PharmaInc (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 92. SPI PharmaInc (US) Business Overview

Table 93. SPI PharmaInc (US) Recent Developments

Table 94. Invivogen (US) Basic Information

Table 95. Invivogen (US) Vaccine Particulate Adjuvants Product Overview

Table 96. Invivogen (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 97. Invivogen (US) Business Overview

Table 98. Invivogen (US) Recent Developments

Table 99. Avanti Polar LipidsInc (US) Basic Information

Table 100. Avanti Polar LipidsInc (US) Vaccine Particulate Adjuvants Product Overview

Table 101. Avanti Polar LipidsInc (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 102. Avanti Polar LipidsInc (US) Business Overview

Table 103. Avanti Polar LipidsInc (US) Recent Developments

Table 104. MVP LaboratoriesInc (US) Basic Information

Table 105. MVP LaboratoriesInc (US) Vaccine Particulate Adjuvants Product Overview

Table 106. MVP LaboratoriesInc (US) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 107. MVP LaboratoriesInc (US) Business Overview
Table 108. MVP LaboratoriesInc (US) Recent Developments
Table 109. OZ Biosciences (France) Basic Information
Table 110. OZ Biosciences (France) Vaccine Particulate Adjuvants Product Overview
Table 111. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 112. OZ Biosciences (France) Business Overview
Table 113. OZ Biosciences (France) Recent Developments
Table 114. Global Vaccine Particulate Adjuvants Sales Forecast by Region (2026-2033) & (K MT)
Table 115. Global Vaccine Particulate Adjuvants Market Size Forecast by Region (2026-2033) & (M USD)
Table 116. North America Vaccine Particulate Adjuvants Sales Forecast by Country (2026-2033) & (K MT)
Table 117. North America Vaccine Particulate Adjuvants Market Size Forecast by Country (2026-2033) & (M USD)
Table 118. Europe Vaccine Particulate Adjuvants Sales Forecast by Country (2026-2033) & (K MT)
Table 119. Europe Vaccine Particulate Adjuvants Market Size Forecast by Country (2026-2033) & (M USD)
Table 120. Asia Pacific Vaccine Particulate Adjuvants Sales Forecast by Region (2026-2033) & (K MT)
Table 121. Asia Pacific Vaccine Particulate Adjuvants Market Size Forecast by Region (2026-2033) & (M USD)
Table 122. South America Vaccine Particulate Adjuvants Sales Forecast by Country (2026-2033) & (K MT)
Table 123. South America Vaccine Particulate Adjuvants Market Size Forecast by Country (2026-2033) & (M USD)
Table 124. Middle East and Africa Vaccine Particulate Adjuvants Sales Forecast by Country (2026-2033) & (Units)
Table 125. Middle East and Africa Vaccine Particulate Adjuvants Market Size Forecast by Country (2026-2033) & (M USD)
Table 126. Global Vaccine Particulate Adjuvants Sales Forecast by Type (2026-2033) & (K MT)
Table 127. Global Vaccine Particulate Adjuvants Market Size Forecast by Type (2026-2033) & (M USD)
Table 128. Global Vaccine Particulate Adjuvants Price Forecast by Type (2026-2033) & (USD/KG)
Table 129. Global Vaccine Particulate Adjuvants Sales (K MT) Forecast by Application

(2026-2033)

Table 130. Global Vaccine Particulate Adjuvants Market Size Forecast by Application
(2026-2033) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Vaccine Particulate Adjuvants
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Vaccine Particulate Adjuvants Market Size (M USD), 2024-2033
- Figure 5. Global Vaccine Particulate Adjuvants Market Size (M USD) (2020-2033)
- Figure 6. Global Vaccine Particulate Adjuvants Sales (K MT) & (2020-2033)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Vaccine Particulate Adjuvants Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Vaccine Particulate Adjuvants Product Life Cycle
- Figure 13. Vaccine Particulate Adjuvants Sales Share by Manufacturers in 2024
- Figure 14. Global Vaccine Particulate Adjuvants Revenue Share by Manufacturers in 2024
- Figure 15. Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Vaccine Particulate Adjuvants Average Price (USD/KG) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Vaccine Particulate Adjuvants Revenue in 2024
- Figure 18. Industry Chain Map of Vaccine Particulate Adjuvants
- Figure 19. Global Vaccine Particulate Adjuvants Market PEST Analysis
- Figure 20. Global Vaccine Particulate Adjuvants Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Vaccine Particulate Adjuvants Market Share by Type
- Figure 27. Sales Market Share of Vaccine Particulate Adjuvants by Type (2020-2025)
- Figure 28. Sales Market Share of Vaccine Particulate Adjuvants by Type in 2024
- Figure 29. Market Size Share of Vaccine Particulate Adjuvants by Type (2020-2025)
- Figure 30. Market Size Share of Vaccine Particulate Adjuvants by Type in 2024
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)

- Figure 32. Global Vaccine Particulate Adjuvants Market Share by Application
- Figure 33. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2020-2025)
- Figure 34. Global Vaccine Particulate Adjuvants Sales Market Share by Application in 2024
- Figure 35. Global Vaccine Particulate Adjuvants Market Share by Application (2020-2025)
- Figure 36. Global Vaccine Particulate Adjuvants Market Share by Application in 2024
- Figure 37. Global Vaccine Particulate Adjuvants Sales Growth Rate by Application (2020-2025)
- Figure 38. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2020-2025)
- Figure 39. Global Vaccine Particulate Adjuvants Market Size Market Share by Region (2020-2025)
- Figure 40. North America Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)
- Figure 41. North America Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)
- Figure 42. North America Vaccine Particulate Adjuvants Sales Market Share by Country in 2024
- Figure 43. North America Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 44. North America Vaccine Particulate Adjuvants Market Size Market Share by Country in 2024
- Figure 45. U.S. Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)
- Figure 46. U.S. Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 47. Canada Vaccine Particulate Adjuvants Sales (K MT) and Growth Rate (2020-2025)
- Figure 48. Canada Vaccine Particulate Adjuvants Market Size (M USD) and Growth Rate (2020-2025)
- Figure 49. Mexico Vaccine Particulate Adjuvants Sales (Units) and Growth Rate (2020-2025)
- Figure 50. Mexico Vaccine Particulate Adjuvants Market Size (Units) and Growth Rate (2020-2025)
- Figure 51. Europe Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)
- Figure 52. Europe Vaccine Particulate Adjuvants Sales Market Share by Country in

2024

Figure 53. Europe Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Vaccine Particulate Adjuvants Market Size Market Share by Country in 2024

Figure 55. Germany Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Vaccine Particulate Adjuvants Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Vaccine Particulate Adjuvants Sales Market Share by Region in 2024

Figure 67. Asia Pacific Vaccine Particulate Adjuvants Market Size Market Share by Region in 2024

Figure 68. China Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Vaccine Particulate Adjuvants Sales and Growth Rate

(2020-2025) & (K MT)

Figure 73. South Korea Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Vaccine Particulate Adjuvants Sales and Growth Rate (K MT)

Figure 79. South America Vaccine Particulate Adjuvants Sales Market Share by Country in 2024

Figure 80. South America Vaccine Particulate Adjuvants Market Size and Growth Rate (M USD)

Figure 81. South America Vaccine Particulate Adjuvants Market Size Market Share by Country in 2024

Figure 82. Brazil Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Vaccine Particulate Adjuvants Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Vaccine Particulate Adjuvants Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Vaccine Particulate Adjuvants Market Size Market Share by Region in 2024

Figure 92. Saudi Arabia Vaccine Particulate Adjuvants Sales and Growth Rate

(2020-2025) & (K MT)

Figure 93. Saudi Arabia Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Vaccine Particulate Adjuvants Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Vaccine Particulate Adjuvants Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Vaccine Particulate Adjuvants Production Market Share by Region (2020-2025)

Figure 103. North America Vaccine Particulate Adjuvants Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Vaccine Particulate Adjuvants Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Vaccine Particulate Adjuvants Production (K MT) Growth Rate (2020-2025)

Figure 106. China Vaccine Particulate Adjuvants Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Vaccine Particulate Adjuvants Sales Forecast by Volume (2020-2033) & (K MT)

Figure 108. Global Vaccine Particulate Adjuvants Market Size Forecast by Value (2020-2033) & (M USD)

Figure 109. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Type (2026-2033)

Figure 110. Global Vaccine Particulate Adjuvants Market Share Forecast by Type (2026-2033)

Figure 111. Global Vaccine Particulate Adjuvants Sales Forecast by Application (2026-2033)

Figure 112. Global Vaccine Particulate Adjuvants Market Share Forecast by Application (2026-2033)

I would like to order

Product name: Global Vaccine Particulate Adjuvants Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/G2FBDDC8F438EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2FBDDC8F438EN.html>